Nuvectis says NXP900 demonstrates robust activity in NSCLC

Nuvectis Pharma (NVCT) recapped poster highlights from the 2024 American Association for Cancer Research AACR conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor EGFR resistant non-small cell lung cancer NSCLC cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC. The data reported, which confirms data previously published by the research team at Astra Zeneca (AZN), demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone. In addition, NXP900 demonstrated potent, single agent, antiproliferative activity in anaplastic lymphoma kinase ALK -resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells. Alectinib is the active ingredient in AlecensaTM, an ALK inhibitor approved for the treatment of NSCLC…Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “We are very pleased to be able to independently confirm the data previously published by the research team at Astra Zeneca, demonstrating the ability of NXP900 to reverse resistance to osimertinib in osimertinib resistant NSCLC cell lines, when administered in combination with osimertinib. We are also pleased with NXP900’s potent single-agent activity in NSCLC cells resistant to alectinib.”